A randomized, double-blind, placebo-controlled trial of prophylactic recombinant human granulocyte-macrophage colony-stimulating factor to reduce nosocomial infections in very low birth weight neonates

Cairo, Mitchell S.; Agosti, Jan M.; Ellis, Robin; Laver, Joseph; Puppala, Bhagya L.; Lemos, Robert de; Givner, Laurence B.; Nesin, Mirjana; Wheeler, J. Gary; Seth, Tulika; Ven, Carmella van de; Fanaroff, Avroy A.

doi:10.1016/s0022-3476(99)70373-2

Cited by 74 publications

(36 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Application of topical emollient ointment for the first 2 weeks of life to minimize skin breakdown was shown in several small trials to reduce transepidermal water loss and decrease dermatitis without changing colonization with bacteria or yeast (66,262,274). Although one single-center study found significantly fewer positive blood or CSF cultures in infants treated with topical emollient compared with controls (48), a multicenter randomized, controlled trial of nearly 1,200 ELBW infants found that topical emollient actually increased LONS, particularly with CoNS.…”

Section: Bacterial Infectionsmentioning

confidence: 99%

Clinical Microbiology of Bacterial and Fungal Sepsis in Very-Low-Birth-Weight Infants

2004

View full text Add to dashboard Cite

Twenty percent of very-low-birth-weight (<1500 g) preterm infants experience a serious systemic infection, and despite advances in neonatal intensive care and antimicrobials, mortality is as much as threefold higher for these infants who develop sepsis than their counterparts without sepsis during their hospitalization. Outcomes may be improved by preventative strategies, earlier and accurate diagnosis, and adjunct therapies to combat infection and protect the vulnerable preterm infant during an infection. Earlier diagnosis on the basis of factors such as abnormal heart rate characteristics may offer the ability to initiate treatment prior to the onset of clinical symptoms. Molecular and adjunctive diagnostics may also aid in diagnosing invasive infection when clinical symptoms indicate infection but no organisms are isolated in culture. Due to the high morbidity and mortality, preventative and adjunctive therapies are needed. Prophylaxis has been effective in preventing early-onset group B streptococcal sepsis and late-onset Candida sepsis. Future research in prophylaxis using active and passive immunization strategies offers prevention without the risk of resistance to antimicrobials. Identification of the differences in neonatal intensive care units with low and high infection rates and implementation of infection control measures remain paramount in each neonatal intensive care unit caring for preterm infants

show abstract

Section: Bacterial Infectionsmentioning

confidence: 99%

Clinical Microbiology of Bacterial and Fungal Sepsis in Very-Low-Birth-Weight Infants

2004

View full text Add to dashboard Cite

show abstract

“…However, despite multiple clinical trials of these agents in neonatal sepsis, they are not in routine usage (5-7). Prophylactic GM-CSF in preterm infants with sepsis has been more successful (8,9) but is not standard therapy either.…”

mentioning

confidence: 99%

Granulocyte Colony-Stimulating Factor and Granulocyte-Macrophage Colony-Stimulating Factor Have Differential Effects on Neonatal and Adult Neutrophil Survival and Function

et al. 2005

View full text Add to dashboard Cite

“…Prophylactic (5) and therapeutic (6) administration of recombinant granulocyte/macrophage colony-stimulating factor (GM-CSF) 1 enhances the survival of neonatal rats during experimental sepsis. Recombinant human GM-CSF has also been shown to increase neutrophil, eosinophil, monocyte, and platelet production in very low-birthweight human newborns (7,8).…”

mentioning

confidence: 99%

Developmental Regulation of RNA Transcript Destabilization by A + U-rich Elements is AUF1-dependent

Buzby

Brewer

Nugent

1999

Journal of Biological Chemistry

View full text Add to dashboard Cite

A randomized, double-blind, placebo-controlled trial of prophylactic recombinant human granulocyte-macrophage colony-stimulating factor to reduce nosocomial infections in very low birth weight neonates

Cited by 74 publications

References 33 publications

Clinical Microbiology of Bacterial and Fungal Sepsis in Very-Low-Birth-Weight Infants

Clinical Microbiology of Bacterial and Fungal Sepsis in Very-Low-Birth-Weight Infants

Granulocyte Colony-Stimulating Factor and Granulocyte-Macrophage Colony-Stimulating Factor Have Differential Effects on Neonatal and Adult Neutrophil Survival and Function

Developmental Regulation of RNA Transcript Destabilization by A + U-rich Elements is AUF1-dependent

Contact Info

Product

Resources

About